Last reviewed · How we verify
Nicardipine , Esmolol
This is a combination of nicardipine (a calcium channel blocker) and esmolol (a beta-1 selective adrenergic antagonist) that work synergistically to reduce blood pressure and heart rate through different pathways.
This is a combination of a calcium channel blocker (nicardipine) and a beta-1 selective adrenergic antagonist (esmolol) that work synergistically to reduce blood pressure and heart rate through different pathways. Used for Acute hypertension management, Perioperative hypertension and tachycardia control.
At a glance
| Generic name | Nicardipine , Esmolol |
|---|---|
| Also known as | Calcium channel blocker |
| Sponsor | Nanjing Medical University |
| Drug class | Calcium channel blocker + Beta-1 selective adrenergic antagonist combination |
| Target | L-type calcium channels; Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nicardipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance. Esmolol is a short-acting beta-1 selective blocker that decreases heart rate and cardiac contractility. Together, they provide complementary antihypertensive and cardioprotective effects, commonly used in acute care settings for rapid blood pressure control.
Approved indications
- Acute hypertension management
- Perioperative hypertension and tachycardia control
Common side effects
- Headache
- Dizziness
- Flushing
- Bradycardia
- Hypotension
- Nausea
Key clinical trials
- The Effects of Nicardipine and Esmolol Applied for Controlled Hypotension (NA)
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) (PHASE3)
- Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery (NA)
- Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage (NA)
- Nicardipine vs Esmolol Craniotomy Emergence (PHASE1)
- The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (NA)
- Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery (PHASE4)
- Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicardipine , Esmolol CI brief — competitive landscape report
- Nicardipine , Esmolol updates RSS · CI watch RSS
- Nanjing Medical University portfolio CI